Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Exelixis, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -1.3300 | -1.470 | 31 | 43 | -244 | -274 | -198 | -222 | -199 | -229 | 50 | 12 |
| 2015 | -1.3800 | -0.846 | 25 | 34 | -268 | -177 | -212 | -124 | -216 | -126 | 50 | 9 |
| 2016 | -0.8100 | -0.433 | 37 | 180 | -169 | 322 | -119 | 33 | -120 | 31 | 57 | 50 |
| 2017 | -0.2800 | 0.490 | 191 | 452 | -70 | 255 | -22 | 293 | -27 | 280 | 116 | 332 |
| 2018 | 0.5200 | 1.286 | 452 | 812 | 154 | 1,244 | 167 | 606 | 165 | 570 | 159 | 267 |
| 2019 | 2.3200 | 0.965 | 853 | 968 | 690 | 232 | 452 | 291 | 438 | 266 | 206 | 172 |
| 2020 | 1.0600 | 0.315 | 967 | 988 | 321 | -224 | 369 | -236 | 369 | -329 | 228 | 275 |
| 2021 | 0.3600 | 0.478 | 987 | 1,338 | 111 | 584 | 110 | 775 | 110 | 731 | 293 | 838 |
| 2022 | 0.7300 | 0.564 | 1,434 | 1,603 | 231 | 677 | 286 | 901 | 286 | 858 | 401 | 810 |
| 2023 | 0.5700 | 0.617 | 1,611 | 1,831 | 182 | 207 | 201 | 999 | 201 | 951 | 459 | 900 |
| 2024 | 0.6500 | 1.669 | 1,830 | 2,152 | 207 | 536 | 196 | 398 | 170 | 371 | 542 | 600 |
| 2025 | - | 1.641 | - | 2,188 | - | 497 | - | 405 | - | 377 | - | 610 |
| 2026 | - | 2.177 | - | 2,444 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 2.780 | - | 2,812 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 3.269 | - | 3,127 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
+9.16% + $3.26 · MISS
Nov. 6, 2024Price Then
$34.77
Price Target
$32.35
Price Now
$35.61